Tag Archives: rare disease research lab

Information Technology in a Pharmaceutical Company

Supporting Rare Disease Research

The process of developing new therapies for rare diseases requires laboratories. That’s obvious, isn’t it? Another critical lab function that may not be so obvious involves quality assurance. All batches of medicines undergo rigorous testing to ensure the manufacturing process produced pure products.

Automation drives and controls medical research labs far more than your chemistry or biology lab courses did in school. Today’s automated lab instruments produce data constantly, recording moment-by-moment conditions in experiments and tests. IT Patch Panel in Rare Disease CompanyRare Disease Company IT Patch Panel

While the format of the data may result in small files, the nature of the data has led to many regulations and requirements for how the data is handled.

Data in Pharmaceutical Companies

Some kinds of data fall under strict guidelines and regulations. Anything that has to do with the manufacture of medicines and the subsequent quality control testing processes remains subject to FDA and international public health agency regulations. Violations of those regulations could actually lead to those public agencies shutting down companies in a matter of minutes. At a very high level, anything, networks and servers included, that could alter the data that would affect manufacturing or lab analysis must be validated, qualified, and controlled rigorously.

What does that mean? When a computer system becomes part of the manufacturing or laboratory environment, extensive tests certify that the application that may control a lab instrument will never invent its own data. This requirement makes sense if you think about it. Variations in data lead researchers to conclude they either have a blockbuster for treatment of a rare disease, or they don’t. If a computer system monitoring temperature of an experiment failed to record or report data for five minutes, how would anyone know if the temperature spiked and recovered, or did nothing abnormal at all?

The same concern applies to control of a manufacturing process. Manufacturing equipment may heat or cool ingredients, and most certainly measure quantities. Moment-by-moment data points assure Pharmaceutical companies and their customers the final product is the same as it has been from the first batch, and remains as safe and as effective as ever.

We all know computers require regular software updates and security-related patches. Microsoft updates usually require system reboots to take effect. Anti-virus software updates can cause a workstation to suddenly block required traffic. Normal IT procedures could have a large negative effect if updates change or disrupt the flow of data in labs or manufacturing.

“Good Manufacturing Practices” in IT in Pharmaceutical Companies

The regulations that control the manufacture of food and drug products create a set of requirements known as “good manufacturing practices” or GMP. A GMP process adheres to the stringent requirements laid out by regulatory agencies worldwide. The industry standard vernacular is “current good manufacturing processes” or CGMP.

GMP regulations or practices affect network design and the configuration management of systems involved in the manufacture or testing of medicines and foods. When a network and systems attached to it connect manufacturing or quality control lab equipment, their configurations have to be validated. Additionally, processes related to changes and maintenance have to be documented.

This complicates the “basic” tasks of network design and architecture. Many network components supporting the business side of a pharma company must change constantly to accommodate new business requirements and protect from new security threats. The two goals of enabling and protecting business operations and supporting manufacturing and disease research seem at odds with each other. However, networking professionals can take measures to satisfy requirements of both interests.

Share This:

Ultra-Rare Disease Challenges

Ultra-Rare Disease Research

Patients suffering from rare life-threatening diseases often have little hope of help from science and medicine after the failure of several initial treatments to effect any results.

The very definition of rare or ultra-rare varies from one in every thousand to one in every 200,000 people afflicted across medical literature and various regulatory agencies worldwide according to Wikipedia

The uncommon nature of a rare disease explains why many doctors may not be able to identify one before a patient succumbs to it. Estimates of more than 7,000 rare diseases worldwide present their own symptoms or combinations of them. Amidst the usual stream of patients with common ailments, it’s easy to understand how doctors may not recognize combinations of symptoms as indicators of one of the many serious and rapidly debilitating diseases.
Rare Disease Research Lab under constructionRare Disease Research Lab Under Construction

For all the diseases that are or have been identified, the FDA has approved fewer than 400 treatments. And, if a treatment or therapy is not FDA-approved to treat a specific disease, a doctor simply can not prescribe it. In other words, even if one drug is eventually approved to treat multiple diseases, a doctor can not prescribe it for anything but the already-approved use before testing and approvals are completed on the additional diseases.

High Cost of Bringing Drugs to Market

The Tufts Center for the Study of Drug Development published a study of the costs to bring a new drug to market in November 2014. They estimate the cost to exceed $2.5 billion.

That figure puts fear into the hearts of investors. The process spans multiple years, and several may pass before research and testing prove great efficacy or a lack of it. The costs of failures do not factor in to the Tufts study. Investors backing start up companies tackling rare diseases have to roll the proverbial dice and patiently wait for the process to unfold. Major pharmaceutical companies have to weigh stock market reaction to write-offs and charges associated with abandoned ineffective therapies. Can you imagine the internal competition for R&D funds for a drug that may have a patient base of millions per year and one that may have a patient population of one thousand?

How Many Patients Have Each Known Rare Disease?

For all the research into rare diseases, estimating the actual market for the drugs remains difficult. Rapidly progressing diseases kill patients before doctors can make accurate diagnoses. The actual prevalence in the world population for any one disease may be underestimated. On one hand, if incidence of one disease is underestimated, investors reap the benefits of additional product sales. If overestimated, a small company may not generate enough revenue to survive.

Rare Disease Drugs Reaching Patients In Time

Some of the known diseases kill the patient within days of diagnosis. Companies can not stock every retail drug store location with medicine for rare disease. A challenge exists on a global scale to shorten the time between diagnosis and drug delivery.

Share This: